Sign-in for customized ASCO content related to your areas of interest.
Explore ACE
Most Viewed
Videos & Slides
2024 ASCO Annual Meeting
A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) in patients with relapsed/refractory B cell non-Hodgkin lymphoma (r/r B-NHL): Updated phase 1 results from the ANTLER trial.
Speaker: Boyu Hu, MD
Date: Jun 3, 2024
Abstract
2024 ASCO Annual Meeting
Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.
First Author: Peter Robert Galle
Date: Jun 4, 2024
Poster
2024 ASCO Annual Meeting
CODOX-M/IVAC-R versus DA-EPOCH-R in double/triple-hit large B cell lymphoma in patients ≤ 60 years.
First Author: Suheil Albert Atallah-Yunes
Date: Jun 3, 2024
Journal
Journal of Clinical Oncology
Chimeric Antigen Receptor (CAR) T-Cell Products for Pediatric Cancers: Why Alternative Development Paths Are Needed
First Author: Claudia Rossig
Publish Date: Nov 27, 2023